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Hepatocellular carcinoma, one of the most commonly occurring cancer, is 
responsible for significant mortality worldwide, with its increasing morbidity, high 
recurrence and poor prognosis. Transarterial chemoembolization (TACE) is 
recommended as the current standard care for patients with intermediate-stage 
hepatocellular carcinoma. However, considering the advantages and disadvantages of 
conventional embolic agents, there is no uniform standard to utilize embolic agents in 
clinic practice. Further, the practice limitations of TACE such as incomplete embolism, 
targeting deficiency, toxic side effects, inferior stability and controllability and 
increasing VEGF levels of residual HCC become more apparent, which accounts for 
the controversial of improving the survival rates of HCC patients. Therefore, the 
urgent demands to development neotype embolic agents have been recognized in the 
clinic treatment of HCC patients. 
On the basis of above-mentioned problems, we adopt an promising anticancer  
strategy of tumor vascular embolization based on targeted coagulation protein. 
Selective thrombosis in hepatocellular carcinoma vessels and induction of subsequent 
tumor infarction is the theoretical foundation of this method. We took tTF (truncated 
tissue factor), the extracellular domain of tissue factor, as the blood coagulation effect 
factor, and chose the oligopeptide EG3287 designed for combination of VEGF165 and 
NRP-1 as the carrier for fusion protein. When tTF is targeted to the tumor vascular by 
the ligand of tTF-EG3287 protein and combines with the cell membrane closely, it 
could induce thrombosis in tumor vasculature and cut off nutrition and oxygen 
supplies of tumor, which results in necrosis of the tumor and produces anti-tumor 
effects. 
To explore the potential antitumor effect of targeted coagulation protein 
tTF-EG3287, the fusion protein was firstly expressed in E.coli BL21 (DE3), purified 















subsequent dialysis. The activities of the fusion protein in vitro were measured by 
coagulation timing and FX activation test. The distribution of the Cy5.5-labelled 
proteins in mice bearing orthotopic H22 hepatocellular carcinoma and normal tissues 
were observed by fluorescence imaging. Finally, the effect of tTF-EG3287 to 
selectively induce thrombosis in hepatocellular carcinoma vasculature was examined 
by histologic analysis, while the expression levels of NRP-1 and VEGFR on normal 
tissue and tumor were detected by immunohistochemistry.  
The results revealed that fusion protein tTF-EG3287 was expressed efficiently in 
E.coli BL21 (DE3) under optimization condition. The coagulation protein was 
purified through Nickel-affinity chromatography column to 95 % purity. The protein 
concentration arrived at 1 mg/ml after refolding and ultrafiltration concentration. The 
activities of the fusion protein in vitro were verified. The coagulation timing and FX 
activation assay showed the superior coagulation activity of tTF-EG3287. In the 
orthotopic H22 hepatocellular carcinoma mouse models, Fluorescence localization 
experiments revealed that tTF-EG3287 could selectively localize in the tumor 
vascular, while NRP-1 and VEGFR were showed high expressed in tumor by 
immunohistochemistry. In histological studies, the selective localization of 
tTF-EG3287 was observed. Blood vessels in the hepatocellular carcinoma in the 
treated group were thrombosed and occluded, and tumor cells around the occluded 
vessels appeared injured and necrosis, with the tumor growth inhibitions of 
tTF-EG3287 up to 68 %. No thrombosis in blood vessels and cell damage, or other 
side effects were observed in normal tissues. 
In summary, targeted coagulation protein tTF-EG3287 was high efficiently 
expressed through prokaryotic expression system. tTF-EG3287 could selectively 
induce thrombosis in orthotopic hepatocellular carcinoma and inhibit the growth of 
tumor. All the survey above may lay the foundation and provide new method for 
development of vascular targeting treatment for hepatic carcinoma.  





















1.transarterial chemoembolization，TACE 经肝动脉化疗栓塞 
2.truncated tissue factor，tTF 截短组织因子 
3.hepatocellular carcinoma，HCC 肝细胞肝癌 
4.polyvinyl alcohol，PVA 聚乙烯乙醇 
5.drug-eluting beads，DEB 药物缓释微球 
6.tumor angiogenesis inhibitor，TAI 新生血管抑制剂 
7.vascular targeting agents，VTA 血管靶向药物 
8.microvessel density，MVD 微血管密度 
9.Neuropilin-1，NRP-1 神经纤毛蛋白 
10.vascular endothelial growth factor，VEGF 血管内皮生长因子 
11.PSMA 前列腺特异性抗原 
12.VCAM-1 血管细胞黏附因子 
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